Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...

Transformational' research aims to create prosthetic hands that not only look natural but also feel intuitive to use ...

Researchers from Bonn and Erlangen identify the protein MLC1 as a target antigen in multiple sclerosis (MS); a chronic ...

A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative condition similar to multiple sclerosis in humans. It also gave researchers a look at how primary ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

ImagesA sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative condition similar to multiple sclerosis in humans ...

< Under the microscope: In the brain section of an MS patient, the neurons are shown in green and the ... University Hospital Bonn (UKB) / Research group Prof. Stefanie Kürten ...